Boehringer was hoping to get some more mileage out of targeted lung cancer med Gilotrif. But those hopes have been dashed by a data monitoring committee.

Worried that GlaxoSmithKline or AstraZeneca might pull up their U.K. roots in the wake of Brexit? Rest easy. Both companies are set to reassure the world this…

Pharma's gifts to politicians--one, in particular--have been in the spotlight since presidential candidate Hillary Clinton announced her VP pick Friday.

Roche won another reprieve in its fight againstthousands of Accutane safety claims. The drugmaker persuaded a New Jersey appeals court to overturn an $18M jury…

Bristol-Myers Squibb’s immunotherapy Opdivo has been powering ahead, racking up sales and new FDA approvals one after another. And with cancer-fighting…

The sun is finally shining on drug company payments to doctors in Europe, and payment information has begun to trickle out.

Valeant just got a new weapon in its battle with AstraZeneca for the opioid-induced constipation throne. But don't expect oral Relistor to power that…

What’s in a new name? For a Takeda and Lundbeck antidepressant, new marketing work.

Tenet Partners is out with its ninth annual evaluation of the most powerful brands, and a pair of pharmas locked up top spots on the list.